5.0 Tirzepatide: the First Therapeutic Step on Mounjaro

Why does 5mg come after 2.5mg rather than being the starting point?

A lot of people assume the starter dose is simply a low-strength version of the real treatment, and that 2.5mg is doing the same job as 5mg, just more gently. That's not quite right. The 2.5mg pen's purpose is adjustment: it gives the body time to get used to a mechanism it hasn't encountered before, reducing the likelihood of pronounced nausea or digestive discomfort when the actual therapeutic dose arrives. The NHS tirzepatide guidance describes this clearly, treatment begins at 2.5mg for four weeks, then the prescriber typically increases to 5mg for the next four weeks.

At 5mg, the dual GIP and GLP-1 receptor activation becomes more clinically significant. Both receptors are involved in appetite regulation and the slowing of gastric emptying, meaning food stays in the stomach longer and fullness signals reach the brain more readily. For many people, 5mg is the first dose at which they notice a clear change in appetite. That said, individual responses vary considerably, which is exactly why titration is prescriber-led rather than automatic.

Practically speaking: you're still using the same style of pen, injecting once a week into the abdomen, thigh, or upper arm, rotating the site each time. The mechanics don't change between doses. What changes is the pharmacological load, and with it the potential for both greater effect and more noticeable side effects, particularly gastrointestinal ones.

What side effects are more likely at 5mg compared to the starter dose?

The most common effects at this stage are digestive, nausea, loose stools, constipation, reflux, or a feeling of fullness that can make regular meal sizes difficult. These tend to be more pronounced after a dose increase than they were at 2.5mg, and they're usually most noticeable in the first week or two after the step up. For most people they ease as the body adapts, though that timeline differs from person to person.

Fatigue and mild headaches can accompany the GI symptoms, especially early on. Injection-site reactions (a small amount of redness or discomfort at the injection point) are also possible. Less common but worth knowing: if you develop severe, persistent stomach pain that radiates to the back, that is a reason to get medical help promptly, because it can be a sign of pancreatitis, a known though infrequent side effect of GLP-1 class medicines, highlighted in an MHRA Drug Safety Update in January 2026.

None of this is meant to alarm; the side-effect profile is well-characterised and the majority of people move through 5mg without significant problems. The important thing is to tell your prescriber how you're getting on, particularly if side effects are affecting your daily life or are persisting beyond the first couple of weeks at the new dose.

Who is likely to stay at 5mg, and who moves on to higher doses?

The Mounjaro licensed schedule runs from 2.5mg up through 5, 7.5, 10, 12.5, and 15mg. The aim, broadly, is to reach the highest dose you tolerate well, because the trial evidence shows a dose-response relationship, with greater average weight reduction at higher doses. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported around 20 to 21% average body-weight reduction at 15mg over 72 weeks.

Some people do stay at 5mg for longer than the standard four weeks, either because their prescriber wants to see a stable response before increasing, or because side effects at a higher dose have meant stepping back down. There's no failure in that. You can read more about the full dose range on our Mounjaro treatment page, and our clinical team's approach to dose review is explained on the about us page.

Eligibility for treatment in the first place centres on having a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol. Lower thresholds apply for some ethnic backgrounds under UK guidance. A prescriber weighs all of this alongside your medical history, BMI alone isn't the whole picture. You can explore the tirzepatide overview for a broader look at the licensed indications, or see how the Mounjaro and tirzepatide relationship is often confused online.

How does 5mg tirzepatide fit into private treatment through a regulated pharmacy?

Tirzepatide is a Prescription-Only Medicine, which means the only legitimate route to it is a prescription following a proper clinical assessment, regardless of whether you're accessing treatment through the NHS or privately. The NHS route currently involves strict eligibility criteria and, in many areas, a waiting list. Private treatment through a GPhC-registered online pharmacy is the alternative for people who either don't meet the current NHS thresholds or would prefer not to wait.

At nume, every consultation is personally read by a GPhC-registered Independent Prescriber. Before any dose increase is authorised, there's a clinical re-review, not a rubber stamp. Our tirzepatide prescribing information covers what that review looks at in more detail, and for context on what the cost picture looks like across private providers, our weight-loss treatments page sets out what's included in one transparent price. There's no subscription and no auto-renewal; each repeat order goes through clinical review.

If you're at the 5mg stage and thinking about whether private treatment is the right path forward, the most straightforward next step is a free consultation, so a prescriber can look at your specific situation rather than a general guide doing it for you.

For anyone comparing treatment options more broadly, the weight-loss overview covers the licensed medicines available in the UK, including how tirzepatide 30 fits into the wider range of doses now available. And if you have specific questions before starting, our FAQs address the ones our prescribers hear most often.